Condition: Pancreatic Cancer · Sponsor: Cambridge University Hospitals NHS Foundation Trust
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
This description comes directly from the study's public registry record.
Clinical Trial Coordinator · +44 01223348454 · cuh.pemola@nhs.net
Early phase team Cambridge Clincial Trials Unit -Cancer Theme · 01223348454 · cuh.cctuep@nhs.net
Always discuss trial participation with your own doctor first.
| Monash Health | Melbourne, Australia | Recruiting |
| Epworth Healthcare | Richmond, Australia | Recruiting |
| Addenbrooke's Hospital | Cambridge, Cambridgeshire, United Kingdom | Recruiting |
| Glan Clwyd Hospital | Bodelwyddan, United Kingdom | Recruiting |
| Velindre Cancer Centre | Cardiff, United Kingdom | Recruiting |
| University Hospitals Coventry and Warwickshire | Coventry, United Kingdom | Recruiting |
| Beatson West of Scotland Cancer Centre | Glasgow, United Kingdom | Recruiting |
| St James' University Hospital | Leeds, United Kingdom | Recruiting |
| Clatterbridge Cancer Centre | Liverpool, United Kingdom | Recruiting |
| Guy's and St Thomas' NHS Foundation Trust | London, United Kingdom | Recruiting |
| Royal Free Hospital | London, United Kingdom | Recruiting |
| University College London Hospitals NHS Foundation Trust | London, United Kingdom | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05093231